



Working in COVID Times

Thank you for following the important guidelines:

- Adhere to occupancy restrictions for each conference room & bathrooms
- Always wear a mask in common areas
- Use hand sanitizer

What's New at BCI

- New picnic tables and chairs have been ordered for the courtyard.
- The A wing of the incubator has a new HVAC system!!
- The next 1:1 Office Hours will address your Emergency Response

SBIR Updates

NSF SBIR 2020 -

Proposals due 12/3/2020

NSF STTR 2020 -

Proposals due 12/3/2020

HHS SBIR/STTR2020-
NIH, CDC, and FDA, SBIR/STTR
2020

Proposals due 1/5,
4/5/2021

Proposals due 1/5,
4/5/2021

In The News

BioAegis Therapeutics Initiates Phase II Trial of Gelsolin, for COVID-19

BioAegis Therapeutics has news!! The Company's recent study assessed BioAegis' therapeutic, recombinant human plasma gelsolin (rhu-pGSN), and its unique ability to regulate the overexuberant inflammatory response, which can cause organ failure and death. Low levels of gelsolin are associated with severe illness and organ failure in COVID-19 patients. BioAegis is developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology. BioAegis is a current resident of the Step-Out Labs and former resident of the Bioscience Center Incubator. [Read more here.](#)

Bellerophon In the News

Former incubator resident, Bellerophon Therapeutics, announced First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19. [More here](#)

Angel Investor Tax Credit Program 2020 Deadline Nov 1st

[The Angel Investor Tax Credit Program offers 20% of a qualified investment made in a NJ emerging technology business.](#) In some cases, a 5% bonus is available.

The deadline for submitting an application is within 6 months from the investment date. Any application submitted after 11/1 or any submitted application that is not complete until after 11/1 will not be considered for a tax credit in 2020. Please note that submitted applications must be complete, with all required documentation including necessary tax clearances for the company and investors. [MORE HERE](#)

New Tenants

Several new residents moved into the Bioscience Center Incubator this year:

Molecular Innovations - drug discovery- products licensed from University of South Florida.

JMS Pharma - pharma contract development and manufacturing with focus on developing sterile formulations ophthalmic nasal, oral, topical.

Sonder RX - Cornell Medical School oncology spin-off with diagnostics and therapeutic solutions for ophthalmic diseases and cancer.

Skunkworx Bio - drug discovery with therapeutics targeting cancer, inflammation, and infectious diseases.

Smirta Innovations - digital health company with a pilot at Tennessee Oncology.

Market Demand & Availability at the New Jersey Bioscience Center

Currently, there is one lab and office package available at the Step-Out Labs. In addition, there is a 5000 SF lab/office unit available at the research park. Read more about the current hot life sciences real estate market in this [CNBC report.](#)

